Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 17/20 | 0.72 |
| ▸ | NQO2 | P16083 | 1/20 | 0.72 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.39 |
| ▸ | VNN1 | O95497 | 1/20 | 0.39 |
| ▸ | CXCR1 | P25024 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23344103 | 1.00 | MET (0.72) | METNQO2CREBBPVNN1CXCR1 | |
| SCHEMBL23344105 | 1.00 | MET (0.72) | METNQO2CREBBPVNN1CXCR1 | |
| Tepotinib SCHEMBL1296895 | 0.83 | MET (1.00) | METNQO2 | |
| Tepotinib SCHEMBL29379106 | 0.83 | MET (1.00) | METNQO2 | |
| Tepotinib SCHEMBL29550043 | 0.83 | MET (0.98) | METNQO2 | |
| Tepotinib SCHEMBL1296467 | 0.83 | MET (0.98) | METNQO2 | |
| Tepotinib SCHEMBL1295616 | 0.83 | MET (0.98) | METNQO2 | |
| Tepotinib SCHEMBL30259391 | 0.83 | MET (0.98) | METNQO2 | |
| SCHEMBL21264639 | 0.82 | MET (0.81) | METNQO2CREBBPVNN1CXCR1 | |
| SCHEMBL21322208 | 0.82 | MET (0.81) | METNQO2CREBBPVNN1CXCR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230365532-A1 | PYRIMIDINE DERIVATIVE AND PREPARATION PROCESS AND USE THEREOF | Guangdong CS-Lewwin Drug Research Co., Ltd. (CN) | 2023-11-16 | — | — | US | disclosed |
| US-20230365532-A1 | PYRIMIDINE DERIVATIVE AND PREPARATION PROCESS AND USE THEREOF | Guangdong CS-Lewwin Drug Research Co., Ltd. (CN) | 2023-11-16 | — | — | US | disclosed |
| US-20210139464-A1 | PYRIMIDINE DERIVATIVE CONTAINING ONE DEUTERIUM ATOM AND PREPARATION PROCESS AND USE THEREOF | Guangdong CS-Lewwin Drug Research Co., Ltd. (CN) | 2021-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210139464-A1 | PYRIMIDINE DERIVATIVE CONTAINING ONE DEUTERIUM ATOM AND PREPARATION PROCESS AND USE THEREOF | DUT, TYMP, DCTD | MET 1807/4885NQO2 758/4885CREBBP 2266/4885 |
| US-20230365532-A1 | PYRIMIDINE DERIVATIVE AND PREPARATION PROCESS AND USE THEREOF | MTR, HCCS, MET | MET 3/4885NQO2 2197/4885CREBBP 2088/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.